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Abstract
Objective: Assessment of the safety and efficacy of a 10-day melarsoprol schedule in second stage T.b. rhodesiense patients
and the effect of suramin-pretreatment on the incidence of encephalopathic syndrome (ES) during melarsoprol therapy.
Design: Sequential conduct of a proof-of-concept trial (n = 60) and a utilization study (n = 78) using historic controls as
comparator.
Setting: Two trial centres in the T.b. rhodesiense endemic regions of Tanzania and Uganda. Participants: Consenting patients
with confirmed second stage disease and a minimum age of 6 years were eligible for participation. Unconscious and
pregnant patients were excluded.
Main Outcome Measures: The primary outcome measures were safety and efficacy at end of treatment. The secondary
outcome measure was efficacy during follow-up after 3, 6 and 12 months.
Results: The incidence of ES in the trial population was 11.2% (CI 5–17%) and 13% (CI 9–17%) in the historic data. The
respective case fatality rates were 8.4% (CI 3–13.8%) and 9.3% (CI 6–12.6%). All patients discharged alive were free of
parasites at end of treatment. Twelve months after discharge, 96% of patients were clinically cured. The mean
hospitalization time was reduced from 29 to 13 days (p,0.0001) per patient.
Conclusions: The 10-day melarsoprol schedule does not expose patients to a higher risk of ES or death than does treatment
according to national schedules in current use. The efficacy of the 10-day melarsoprol schedule was highly satisfactory. No
benefit could be attributed to the suramin pre-treatment.
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Introduction
Human African Trypanosomiasis (HAT), better known as
sleeping sickness, is transmitted through tsetse flies (Glossina ssp.).
The disease occurs in a chronic form caused by Trypanosoma brucei
gambiense (West and Central Africa) and an acute form caused by
Trypanosoma brucei rhodesiense (East and South Africa). Both forms of
HAT are fatal if left untreated. Time to death has been estimated
at almost 3 years for T.b. gambiense [1] and at 6 to 12 months for
T.b. rhodesiense infections [2].
Estimating the true prevalence of sleeping sickness is difficult as
less than 10% of the at risk population are under adequate
surveillance [3]. The majority of reported cases are T.b. gambiense
infections [4], and T.b. rhodesiense HAT is clearly more neglected.
However, rhodesiense sleeping sickness has a dangerous potential
for large scale epidemics which are of high public health
importance [5]. Between 1976 and 1998 a total of 19’974 cases
were detected in south eastern Uganda [6], an area that today, has
the potential for a much larger number of patients due to the
expansion of HAT to previously disease free areas [7,8]. The
disease mainly affects local people but sporadic infections in
tourists, especially in National Parks, occur and have spurred
discussions about disease control and surveillance [9].
Sleeping sickness progresses from the first, haemolymphatic
stage, where parasites are detectable in blood and lymph to the
second, meningo-encephalitic stage where parasites enter the
central nervous system. Clinical signs and symptoms of second
stage disease are severe sleep disturbances, neurological and
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psychiatric disorders, coma, and death. A lumbar puncture is
required for disease staging. The second stage is indicated by the
presence of trypanosomes and/or elevated levels of white blood
cells ($5WBC/mm3) in the cerebrospinal fluid (CSF) [3]. For the
treatment of T.b. gambiense HAT, pentamidine is used to treat the
first stage and eflornithine, a combination of eflornithine and
nifurtimox (NECT) or melarsoprol to treat second stage infections.
T.b. rhodesiense infections are treated with suramin in the first, and
melarsoprol in the second stage. Eflornithine can only be used for
the treatment of T.b. gambiense HAT due to its limited activity
against T.b. rhodesiense [10]. NECT has been recommended as new
first line treatment for T.b. gambiense HAT [11] and was added to
the WHO Essential Medicine List in 2009 [12]. The NECT
implementation is currently ongoing in T.b. gambiense affected
areas. For T.b. rhodesiense HAT, melarsoprol remains the only
available drug to treat second stage infections.
Melarsoprol is a highly toxic, arsenical compound and was first
introduced in 1949 [13]. Treatment regimens were empirically
developed and vary considerably between countries and treatment
centres. Complicated dosing schemes, based on serial drug
applications separated by 1-week drug-free intervals, are common
and result in hospitalization times of up to one month. The most
severe complication of melarsoprol therapy is the encephalopathic
syndrome (ES). It appears to be more common in T.b. rhodesiense
than in T.b. gambiense HAT, with reported incidence rates ranging
from 5–18% [14]. The concomitant use of steroids during
melarsoprol therapy proved to reduce the incidence of ES in
T.b. gambiense patients [15] but this could not be shown in T.b.
rhodesiense [16,17]. In East Africa, the heterogeneity of treatment
protocols is further enhanced by the fact that some counties
(Tanzania, Uganda, parts of Malawi) administer a suramin pre-
treatment. It is given prior to the diagnostic lumbar puncture and
should (i) prevent a mechanical introduction of trypanosomes into
the CNS during the LP and (ii) clear trypanosomes from blood and
lymph to avert initial high antigen releases at the initiation of
melarsoprol therapy. Treatment protocols for the suramin pre-
treatment are also heterogeneous and in practice, suramin is not
given to critically ill patients to quickly reach curative melarsoprol
concentrations in the CNS. The use of the suramin pre-treatment
is purely empirical [18] and there is no solid evidence supporting
this approach. Table 1 summarizes the national treatment
schedules currently in use for the treatment of second stage T.b.
rhodesiense HAT in East Africa. The total amount of melarsoprol
administered and the hospitalization time are also shown.
The first, rational approach to a standardized melarsorpol
treatment was the development of a treatment schedule based on
pharmacokinetic investigations [19,20]. The new schedule consists
of daily melarsoprol injections (2.2 mg/kg) for 10 consecutive
days. It was validated for second stage T.b. gambiense HAT in the
framework of the IMPAMEL I & II programs (1997–2004). Results
showed that the abridged schedule is clinical non-inferior over the
empirical standard regimens [21] and equally effective [22]. The
10-day schedule was clearly favored by patients and health
personnel due to an .50% reduction in hospitalization time and a
more economic use of the drug [23]. In 2003, the 10-day
melarsoprol schedule was officially recommended for use in T.b.
gambiense affected areas by the International Scientific Council for
Trypanosomiasis Research and Control (ISCTRC).
Due to the significant differences in the two forms of HAT it
was not possible to introduce the 10-day melarsoprol schedule in
T.b. rhodesiense endemic areas without further testing. The WHO
scientific working group recommended the urgent conduct of the
necessary clinical trials in East Africa (2001), a call that was
repeated by WHO Afro in 2003. The IMPAMEL III program (2005–
2009) was conducted as the first clinical trial program in
accordance to international standards in T.b. rhodesiense patients.
It assessed the safety and the efficacy of the 10-day melarsoprol
schedule in second stage T.b. rhodesiense patients and the effect of
suramin-pretreatment on incidence of serious adverse events
during melarsoprol therapy. Given the limited number of T.b.
rhodesiense patients, clinical trials are evidently restricted to small
sample sizes and must be executed in rural settings with very
limited infrastructure and difficult access. Randomized controlled
trials or other trial designs with active control groups are therefore
not feasible. The design of the IMPAMEL III program was to
conduct two sequential trials: first a proof-of-concept trial was
conducted to proof no harm of the 10-day melarsoprol schedule in
T.b. rhodesiense patients and to obtain preliminary efficacy data.
Two subgroups, of which only one received suramin, allowed
observing a possible, substantial increase of adverse drug reactions
if melarsoprol was directly administered. Based on those findings,
a second trial was designed to substantiate the results in a larger
patient population. The second, drug utilization trial, was designed
as an extension of the selected arm of the proof-of-concept trial,
i.e. without suramin, thus, allowing pooling data from both trials
for final analysis. Patient records from a maximum of two years
prior to the IMPAMEL III program were analyzed and used as
comparator. The findings of the two sequentially conducted trials
are reported here collectively.
Methods
Ethics Statement
Ethical clearance was obtained from the ethics committees in
the host countries; the National Institute for Medical Research
(NIMR), Tanzania and the Ministry of Health, Uganda. In
Switzerland, ethical clearance was obtained from the ethics
committee of the two cantons of Basel (EKBB). Each participant
gave written informed consent. For the participation of children
and adolescents (below 18 years) the parents, the legal represen-
tative or the guardian gave written informed consent. The trials
were registered with Current Controlled Trials prior to first
patient enrolment (ISRCTN40537886). The trials were conducted
Author Summary
Human African Trypanosomiasis (HAT) is a parasitic disease
that occurs in a chronic form caused by T.b. gambiense in
West and Central Africa and in an acute form caused by
T.b. rhodesiense in East and South Africa. In the first stage
of the disease parasites are detectable in blood and lymph.
Once they enter the central nervous system, patients are in
the so-called second stage, which is fatal if left untreated.
Melarsoprol, an old and highly toxic drug, remains the only
available treatment for second stage T.b. rhodesiense HAT.
The empirically developed treatment regimens are a high
burden to affected patients and health care providers due
to very long hospitalization times and complicated dosing
schemes. An improved 10-day melarsoprol treatment
schedule was developed and tested in second stage T.b.
gambiense patients from 1997–2004 and was approved for
large-scale use by the International Scientific Committee
for Trypanosomiasis Research and Control (ISCTRC) in
2003. To test its adequacy also in T.b. rhodesiense patients,
a series of clinical trials were conducted from 2005–2009.
Based on these results the ISCTRC has officially recom-
mended the use of the 10-day melarsoprol schedule also
for treatment of second stage Rhodesiense HAT in 2009.
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in compliance with ICH/GCP. For the use of historic controls,
data was anonymized.
Study Sites
The Kaliua Health Centre (KHC), a 50-bed missionary hospital
in Tanzania (Urambo District) and the Lwala Hospital, a
designated 100- bed district hospital in Uganda (Kaberamaido
District) participated in the IMPAMEL III program. Capacity
building included on-site trainings in HAT diagnosis, Good
Clinical Practice (GCP) and the upgrading of the laboratories and
pharmacies.
Study Design
Sequential conduct of two non-randomized trials; a proof-of-
concept trial (n = 60) followed by a utilization study (n= 78) using
historic data as comparator (n = 300).
Proof-of-concept trial (Protocol S1). 60 patients were
prospectively enrolled into two subgroups: participants in the first
subgroup (n= 30) were treated with the suramin pre-treatment
followed by the 10-day melarsoprol schedule. The second sub
group (n = 30) was directly treated with the 10-day melarsoprol
schedule. Suramin and steroids were administered according to
centre specific guidelines.
Utilization study (Protocol S2). Additional 78 patients were
treated with the 10-day melarsoprol schedule directly. The
suramin pre-treatment was omitted and the use of steroids was
adjusted to the Tanzanian standard in both centers (details below).
Eligibility Criteria
Patients with confirmed second stage T.b. rhodesiense HAT and a
minimum age of 6 years were eligible for participation. Pregnant
as well as unconscious or moribund patients were excluded from
the trial. Each participant gave written informed consent. For the
participation of children and adolescents (below 18 years) the
parents, the legal representative or the guardian gave written
informed consent.
Diagnosis and Staging
Diagnosis of HAT was made in blood and in the cerebrospinal
fluid (CSF). Blood was examined using microscopy and/or the
haematocrit centrifugation technique (WOO test) [24]. If
trypanosomes were present, a lumbar puncture was performed
for disease staging. Patients in the first subgroup of the proof-of-
concept trial received the suramin pre-treatment prior to the LP.
All other patients underwent LP directly after the detection of
trypanosomes in blood. Analysis of the CSF was done by direct
microscopy and/or single modified centrifugation technique and
white blood cell (WBC) count using counting chambers. Second
stage infections were confirmed by the presence of trypanosomes
and/or $5 WBC/mm3 in the CSF.
Patient Follow-Up
All patients were asked to present at the centre for follow-up
examinations after 3, 6 and 12 months. At each follow-up visit
blood and CSF samples were taken and were analyzed for the
presence of trypanosomes. A WBC count was performed using the
CSF sample. For patients who did not present for follow-up visits,
oral information on their general condition was collected.
Endpoints: Safety & Efficacy
Based on reported case fatality rates in the trial sites and the
literature, a cut-off point of all-cause mortality was set at $10%.
The computed safety stopping rule was an early discontinuation of
the trials if 7 or more patients per subgroup (n= 30) experienced a
fatal treatment outcome (p= 0.026).
The primary efficacy endpoint was cure at end of treatment.
Secondary efficacy endpoint was cure after 3, 6 and 12 months.
Possible outcome measures are summarized in Table 2.
A high degree of homogeneity in the trial populations was
achieved by the use of identical eligibility criteria, stopping rule
and endpoints in both trials.
Historic Controls
To reduce bias, historic controls were solely collected in the two
trial sites and limited to a time frame of maximum two years prior
to study initiation. Files that contained basic demographic data
and information on treatment and treatment outcome were
selected and checked for information on serious adverse events
(SAEs), concomitant treatments and death. The same exclusion
criteria as in the trial population were applied to historic controls.
The files were sufficiently documented to exclude patients below 6
years of age and pregnant women. There was insufficient
information to systematically exclude unconscious and moribund
patients. A total of 300 files were used as historic controls (153 in
Tanzania, 147 in Uganda).
Table 1. National treatment schedules for 2nd stage T.b. rhodesiense HAT.
Uganda Tanzania Kenya Malawi
Suramin pre-treatment (mg/kg)
1st dose 5 5 NA 5
2nd dose 20 NA 20
Melarsoprol treatment (mg/kg)
1st series 0.5, 0.72, 1.08 2.2, 2.52, 2.88 3.6, 3.6, 3.6 3.6, 3.6, 3.6
2nd series 1.44, 2.80, 2.2 2.88, 3.24, 3.6 3.6, 3.6, 3.6 3.6, 3.6, 3.6
3rd series 2.52, 2.88, 3.24 3.6, 3.6, 3.6 3.6, 3.6, 3.6 3.6, 3.6, 3.6
4th series 3.6, 3.6, 3.6 3.6, 3.6, 3.6
Total melarsoprol (mg/kg) 27 28.08 43.2 32.4
Hospitalization time (days) 29 27 33 26
NA:not applicable; i.v. melarsoprol injections at 24 hours intervals per series, each series spaced by 5 to 7 days resting periods; further variations of the schedules at local
level.
doi:10.1371/journal.pntd.0001695.t001
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Sample size
No formal sample size was calculated for the proof-of-concept
trial. The sample size calculation for the utilization was based on
the accuracy of the occurrence of the safety endpoint. A minimum
of 100 patients estimated the probability of the occurrence of all-
cause mortality $10% with a standard error of 3%.
Analysis Plan
In a first step both trials were analyzed separately. Final safety
and efficacy analysis was performed on the pooled dataset of all
patients directly treated with the 10-day melarsoprol schedule
(n = 107). Those results were compared to historic controls.
Recruitment
Patient recruitment was mainly by passive case detection at the
centre. Active case search was done in villages of index cases, but
the outcome was poor. In Uganda, the local radio station was
contracted to inform the population about the IMPAMEL III
program and invited people to present for cost-free HAT
screening at the Lwala hospital.
All trial participants were given an insecticide treated bed net
(ITN). In case of need, the trial participants and/or their
attendants were given food during the hospitalization period.
Cost of transport for the patient and one attendant to present for
follow-up visits was refunded.
Data Management and Statistical Analysis
All data were double entered and verified using the EpiData
Version 3.1 software (www.epidata.dk). Data analysis was done using
the statistical software package STATAVersion IC10.0 (STATATM,
StataCorp, USA). Pearson’s chi-square test and the Student’s t-test
were used to test differences in proportions and means.
Trial Conduct
For each patient, a case report form (CRF) was filled containing
information on demographic, diagnostic, and clinical character-
istics before and after treatment. The assessment of adverse events
used a graded scale for the severity of the event (0 to 4, absent to
severe) and a binary outcome for the seriousness of the event. Signs
and symptoms which were spontaneously reported between the
end of treatment evaluation and 30 days post-treatment were also
entered in the case report form.
During the proof-of-concept trial, the blood sugar and the blood
lipids were monitored daily before food intake using the whole
blood test system Cardio ChekTM PA. As suramin is nephrotoxic,
proteinuria was monitored in all patients that received suramin at
baseline and discharge examination as well as prior to the first
melarsoprol application (using COMBUR9, Roche Diagnostics
Switzerland).
During both trials, vital signs were daily monitored before drug
administration. For women, a pregnancy test was performed at
baseline.
Patients were treated with anti-malarial and anti-helminth drugs
prior to HAT treatment in case the respective diagnosis was
positive. During treatment, all patients received paracetamol
(acetaminophen) 3 times per day in single doses of 1000 mg for
adults and 500 mg or 250 mg respectively for children. Suramin
was administered intravenously as a 10% aqueous solution
(Germanin, Bayer). In the proof-of-concept trial, suramin as well
as steroids were given according the centre-specific guidelines. In
Tanzania, a suramin test dose (5 mg/kg) was administered after
the detection of trypanosomes in blood (day 1). After a resting day,
a full dose (20 mg/kg) was given on day 3. Another resting day
followed before the LP on day 5. Each patient was treated with
10 mg of prednisone half an hour before each melarsoprol
injection. In Uganda, patients received one suramin test dose
(5 mg/kg) after the detection of trypanosomes in the blood. On the
following day, the LP was performed and melarsoprol treatment
was initiated. Steroids were only administered in case of reactions
to treatment. Melarsoprol treatment was for all patients 2.2 mg/kg
of melarsoprol for 10 consecutive days as a 3.6% solution in
propylene glycol (Arsobal; Sanofi-aventis); by slow intravenous
(i.v.) injection but maximally 5 ml a day. In the utilization study,
all patients underwent LP directly after a trypanosome-positive
blood test, the use of steroids was adapted to the Tanzanian
standard and the use of suramin was omitted.
If a patient developed an encephalopathic syndrome (ES)
defined by the occurrence of convulsions, and/or confusion, coma
[25], melarsoprol treatment was interrupted and emergency
treatment was initiated: i.v. hydrocortisone (100–200 mg/
24 hours) or dexamethasone (3615 mg/24 hours) and if neces-
sary, anticonvulsive drugs (diazepam, phenobarbital) were admin-
istered. Close observation and frequent monitoring of vital signs
were mandatory as well as supportive feeding, if necessary. For
Table 2. Possible safety and efficacy outcome measures of IMPAMEL III trials.
Cure at end of treatment No parasites in blood and CSF
Cure during follow-up No parasites in blood and CSF AND WBC,5/mm3
Clinical cure at end of treatment No parasites in blood but missing results on CSF analysis (refusal of LP, hemorrhagic
LP)
Clinical cure during follow-up No parasites in blood but missing results on CSF analysis (refusal of LP, hemorrhagic
LP) OR Oral information on good general condition of the patient
Relapse (end of treatment and during follow-up) Trypanosomes in any body fluid
Death Patients who died during treatment or follow-up (categorized by likely or definite
cause of death):
- HAT
- Adverse events regarded by the investigator as possibly or probably related to
treatment for HAT
- Causes unrelated to HAT or the treatment of HAT
- Unknown causes
doi:10.1371/journal.pntd.0001695.t002
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exclusion of cerebral malaria, blood was analyzed at the day of
onset of the ES.
Results
First, the results of the proof-of-concept trial are presented,
followed by the results of the pooled data set and the comparison
to the historic data.
The study flow is presented in Figure 1.
Proof-of-concept Trial
Study population and baseline characteristics. From
August 2006 to July 2007 a total of 60 patients were enrolled.
The age and sex distribution were similar in both sites. The
median age in Uganda (31 years) was slightly lower than in
Tanzania (36 years) as 10 participants were between 6 and 15
years of age. Malnutrition (BMI,16.5) was more common in
Uganda (p = 0.001). In Tanzania, patients had less frequently
trypanosomes in the CSF (p = 0.0035) but significant higher WBC
counts (p,0.0001). The majority of patients suffered from
headaches (90%), general malaise (93.3%) and joint pains
(86.7%). Fever (axillary .37.5uC) at baseline was recorded in
35% of all patients.
Safety. A total of 13 serious adverse events (SAE) were
reported whereof 7 (53.8%) were fatal. Other SAEs included
prolonged hospitalizations and events that required medical
interventions. More ES were reported in Uganda than in
Tanzania (6 vs. 1; p= 0.0444). The time to onset of the ES was
between 3 and 11 days after the first melarsoprol dose (median 6,
mean 7). The overall survival rate for the ES was 28.6% (0% in
Tanzania and 33% in Uganda). Adverse events reported included
headache (15%), vomiting (13%), febrile reactions (13%), diarrhea
(8.3%), nausea (6.6%), dizziness (5%), skin reactions (1.6%) and
were controlled by symptomatic treatment. 56.7% of patients had
an event free treatment course.
Efficacy. 24 hours after treatment, all patients discharged
alive (53/60) were free of parasites in blood and CSF. During
follow-up, 2 relapses were reported, one from Tanzania and one
from Uganda. The patient from Tanzania had been treated with
melarsoprol only. 11 months after discharge he returned to the
centre because he started to feel sick again after experiencing
multiple tsetse bites and was diagnosed with second stage HAT.
The patient from Uganda returned two weeks after discharge and
was diagnosed with first stage HAT. He had been treated with
suramin and melarsoprol and developed an ES after the 6th
injection of melarsoprol. The treatment was interrupted for 8 days
and then resumed for the remaining 4 doses. Both relapse cases
were successfully re-treated with melarsoprol according the
national treatment schedules. Overall safety and efficacy outcomes
of the proof-of-concept trial are summarized in Table 3. Results of
blood sugar, blood lipids and urine analysis are not shown here.
Follow-up attendance was poorer in Tanzania, most probably
due to longer distances to the health centre. 44% of the patients
presented for the 3 months follow-up and 30% and 19% for the 6
Figure 1. Overall study flow chart.
doi:10.1371/journal.pntd.0001695.g001
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and 12 months, respectively. In Uganda, 88% presented for the 3
months follow-up, 65% for the 6 months and 54% for the 12
months follow-up. For all patients not seen at the centre, oral
information on their general condition was collected. All were in
good condition and working, except one patient from Tanzania
who died 7 months after discharge for reasons not related to HAT.
No benefit could be attributed to the suramin pre-treatment. In
contrast, there were more ES and fatal treatment outcomes in the
suramin group (see Table 3).
Utilization Study
A total of 78 patients were enrolled from October 2007 to
August 2008. For final analysis data from the proof-of-concept
study (without suramin) and the utilization study were pooled.
Table 4 compares the two patient populations prior to data
pooling. None of the parameters were significantly different.
Study population and baseline characteristics. The
demographic, diagnostic, and clinical characteristics of the patients
were similar in Tanzania (Tz) and Uganda (Ug). 19 trial
participants (Tz: 2, Ug: 17) were below 16 years of age with a
mean age of 11 years (63 years). Malnutrition (BMI,16.5) was
significantly more frequent in Uganda (p,0.0001). In Tanzania,
patients had less frequently trypanosomes in the CSF (p= 0.0002)
but significantly higher WBC counts (p,0.0001). In line with the
significant higher WBC count, the neurological symptoms were
more distinct in Tanzanian patients. The clinical presentation of
the disease in the two geographically distinct areas has been
published separately [26].
Safety. A total of 27 SAEs were reported, summarized by
SAE criterion in Figure 2. 33.3% (9/27) of the SAEs were fatal
and included one death due to advanced HAT and 8 deaths due to
ES. 14.8% (4/27) SAEs were life threatening events (non-fatal ES).
22.2% (6/27) SAEs were based on prolonged hospitalizations of
patients who were kept for observation due to general weakness.
29.6% (8/27) SAEs were medical events and included treatment of
malaria, severe vomiting, severe headache, cardiac arrhythmia
and psychosis at end of treatment.
9 patients died during treatment. Death occurred between 2
and 16 days (median 9, mean 8.5) after the first injection of
melarsoprol and the major cause was ES (88.9%). The onset of ES
was reported after an average of 7.5 days after the first dose of
melarsoprol (range 3–10 days). The onset was sudden, in 58.3%
(7/12) preceded by headache and fever and in 41.6% (5/12) by
vomiting. In 16.6% (2/12) malaria parasites were detected at the
onset of ES, which probably also caused fever and headache.
Differences were observed in the duration of ES; in Tanzania they
were fatal after a maximum of one day and in Uganda the ES
could last for several days (range 1–8) until the patient’s condition
improved or deteriorated. The overall ES survival rate was 33.3%
(Tz: 0%; Ug: 57.1%).
Other adverse events reported included febrile reactions (37%),
headache (22%), vomiting (13%), dizziness (9%), skin reactions
(6.5%), nausea (5.6%) and diarrhea (4%). 35.5% the patients had
an event-free treatment.
Efficacy. All patients discharged alive (98/107) were free of
parasites in blood and CSF 24 hours after treatment. The follow-
up attendance was better in the utilization study, most likely due to
a better understanding of its importance. Follow-up attendance
rates in Tanzania were 69% at the 3 months, 97% at the 6 months
and 34% at the 12 months follow up. In Uganda 91% presented
for the 3 months follow-up, 46% for the 6 months and 57% for the
12 months follow-up. For all patients that did not present at the
centre, oral information on their well being was collected.
During follow-up, two deaths occurred in Tanzania whereof
one occurred in a patient enrolled into the proof-of-concept trial
(see above). The patient from Tanzania enrolled into the
utilization study died 9 months after discharge due to reasons
not related to HAT. One patient from Uganda died 2 months after
discharge of unknown reasons. Table 5 summarizes the main
safety and efficacy outcomes of the pooled data set at discharge
and at 12 months after treatment.
Historic Data and Comparison to Trial Data
In both centers all HAT patient files from 2004–2006 were
reviewed. A total of 300 files were selected, excluded were
incomplete patient files (missing information on demographics
and/or treatment evolution). The demographics, the incidence of
ES and death as reported in the historic patient files are shown in
Table 6.
In the historic data the mean reported incidence of ES in the
historic data was 13% (Tz: 11.1%, Ug: 15%), of which 67.9%
were fatal. The hospitalization time was 27 days in Tanzania and
32 days in Uganda (range 3–92). For trial patients directly treated
Table 3. Proof-of-concept trial: safety & efficacy outcomes at discharge and follow-up.
Total Suramin Non-suramin
Patients treated n=60 % n=30 % n=30 %
Encephalopathic syndrome 7 11.6 4 13.3 3 10
Death during treatment 7 11.6 5a 16.6 2a 6.6
Relapses at discharge 0 0 0
Cure at end of treatment 53 88.3 25 83.3 28 93.3
Patients eligible for follow-up n=53 n=25 n=28
After 12 months
Death 1 1.8 0 1b 3.6
Relapses 2 3.8 1 4.0 1 3.6
Clinical cure during follow-up 50 94.3 24 96 26 92.9
NOTE:
atwo patients from Tanzania had an incomplete treatment and died outside the centre after family members took them back to the village to seek local treatment;
bnot related to HAT (Tanzania).
doi:10.1371/journal.pntd.0001695.t003
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with melarsoprol, the mean hospitalization time was 13 days
(range 3–34) (p,0.0001). Given the significantly shorter hospital-
ization time, fewer patients in the trial population left the hospital
prior to completion of treatment than compared to historic control
(99% vs. 97%).
Comparison between trial and historic data for ES, case fatality
rate (CFR) and hospitalization time is shown in Figure 3.
Discussion
Given the significant differences between the chronic and acute
form of HAT the results of the IMPAMEL I&II programs could not
be directly extrapolated to T.b. rhodesiense HAT and further testing
was needed. In the planning of the IMPAMEL III program,
treatment efficacy was not the major concern as the total exposure
time of the parasite to melarsoprol is similar in the empirical
schedules and the IMPAMEL schedule: in Tanzania, melarsoprol is
given for 9 days (363) and in Uganda for 12 days (364), spaced by
resting periods, versus a total of 10 consecutive days according the
abridged schedule. Also, the IMPAMEL schedule was extensively
tested in second stage T.b. gambiense patients and yielded similar
cure rates as the empirical schedules [22]. The main concerns
were related to unexpected toxicity: given the already higher
parasitaemia and reported incidence of ES in T.b. rhodesiense
patients, a further increase of ES under the 10-day melarsoprol
schedule could not be excluded. However, evidence from studies
in T.b. gambiense HAT showed that the pathogenesis of ES is an
immune phenomenon and dose independent [27]. Hence, the 10-
day melarsoprol schedule should theoretically not trigger an
increase in the incidence of ES in T.b. rhodesiense patients.
Suramin Pre-treatment
Pre-treatment with pentamidine and suramin have been given
for decades in the hope of reducing the risk for ES, but this
remains unproven [14]. In Tanzania, and the southern parts of
Malawi the suramin pre-treatment consist of a test dose (5 mg/kg)
and a full dose (20 mg/kg) administered over a time period of 5
days. In Uganda, a test dose (5 mg/kg) is given the day before the
LP which, from a pharmacological point of view, is unlikely to
efficiently clear trypanosomes as suramin is only taken up slowly
by the parasite [28]. The suramin pre-treatment is not given to
critically ill patients to quickly reach antitrypanosomal activity in
the CNS. In Kenya and northern parts of Malawi the suramin pre-
treatment is not part of second stage HAT treatment protocols.
Because it was not possible to deviate from current national
treatment protocols in one step, the assessment of the ability of the
suramin pre-treatment to prevent adverse drug reactions was part
of the IMPAMEL III trial design, despite the lack of scientific
evidence. We observed more adverse events during the proof-of-
concept trial in patients that received suramin (63.3%) than in
patients that were directly treated with melarsoprol (23.3%,
p= 0.0018). Based on this result we decided to omit the suramin
pre-treatment in the utilization study. In the pooled dataset, where
none of the patients received suramin, 61.7% of the patients
Table 4. Baseline characteristics of patient populations prior to data pooling.
Proof-of-concept1 Utilization study Pooled dataset
n=30 % N=77 % n=107 %
Age, mean6SD 36618 37619 36619
Age, range (years) 6–67 6–72 6–72
Male/female ratio 1.7 1.3 1.4
Nutritional status
BMI2 (kg/m) mean6SD 18.863.4 18.663.6 18.663.5
Severe malnutrition (BMI,16.5) 8 26.6 18 23.4 26 24.3
Diagnostic findings
Trypanosomes in blood 30 100.0 72 93.5 102 95.3
Trypanosomes in CSF3 28 93.33 69 89.6 97 90.7
WBC4 count in CSF 92657 78664 82662
Clinical manifestations
Headache 27 90.0 73 94.8 100 93.5
Fever (.37.5) 7 23.3 13 16.9 20 18.7
Oedema 6 20.0 25 32.5 31 29.0
Joint pains 29 96.7 76 98.7 105 98.1
Daytime sleep 24 80.0 63 81.8 87 81.3
Night time sleep 23 76.7 50 64.9 73 68.2
Abnormal movements 8 26.7 20 26.0 28 26.2
Walking difficulties 13 43.3 53 68.8 66 61.7
Time period of enrolment Oct 06–May 07 Oct 07–Aug 08 Oct 06–Aug 08
Note:
1no suramin pre-treatment;
2body mass index,
3cerebrospinal fluid,
4white blood cell.
doi:10.1371/journal.pntd.0001695.t004
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experienced adverse events. We observed no benefit of suramin
pre-treatment over the direct melarsoprol application.
Safety
35% of all patients treated directly with melarsoprol had an
event-free treatment course. Concomitant treatments were less
frequently used in the trial population compared to the historic
data (p = 0.0001). Adverse events such as vomiting, headache, skin
reactions and fever were controllable with concomitant medica-
tions. Skin reactions (rashes, pruritus) were a minor problem,
reported in 6.5% of the patients. This was surprisingly low given
the high incidence of severe skin reactions in T.b. gambiense patients
(28.4%) of which 4.2% were fatal (bullous eruptions) [23]. The
most relevant safety outcome of melarsoprol treatments is the
incidence of serious adverse events (ES and death). A systematic
literature review on encephalopathic syndromes during melarso-
prol treatment of HAT [29] reported incidence rates of ES and
death in T.b. rhodesiense patients of 10.6% (1.5–28%) and 11.6%
(CI 5.2–19%) respectively. This compared well to the historic data
where we report incidence rates of ES and death of 13% (CI 9.2–
Table 5. Utilization trial: safety & efficacy outcomes at
discharge and follow-up.
Total Tanzania Uganda
Number of patients treated n=107 % n=54 % n=53 %
Encephalopathic syndrome 12 11.2 5 9.3 7 13.2
Death during treatment 9 8.4 5 9.3 4 7.5
Relapses at discharge 0 0 0
Clinical cure at discharge 98 91.6 49 90.7 49 92.5
Patients eligible for follow-up 98 49 49
At 12 months
Death 3 3.1 2a 4.1 1 2
Relapses 1 1.0 1a 2.0 0
Clinical cure 94 95.9 46 93.9 48 98.0
NOTE:
aone death and relapse enrolled and reported in proof-of-concept trial.
doi:10.1371/journal.pntd.0001695.t005
Table 6. Demographics and incidence of ES and death in
historic patient files.
Total Tanzania Uganda
Number of patients n =300 % n=153 % N=147 %
Age, mean 6 SD 29616 346171 256172
Male/female ratio 1.4 2.5 0.8
Encephalopathic syndrome 39 13.0 17 11.1 22 15.0
Death 28 9.3 12 7.8 16 10.9
1missing values for age: 18,
2missing values for age: 3.
doi:10.1371/journal.pntd.0001695.t006
Figure 2. Serious adverse events, by SAE criterion.
doi:10.1371/journal.pntd.0001695.g002
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Figure 3. Mean and 95% CI for ES, CFR and hospitalization time. Trial data (solid line) and historic data (dashed line).
doi:10.1371/journal.pntd.0001695.g003
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16.8%) and 9.3% (CI 6.0–12.6). In the trial population the
incidence rates of ES and death were 11.2% (CI 5.1–17.3) and
8.4% (CI 3–13.8), respectively.
Findings from T.b. gambiense HAT of a higher risk for ES
associated with the presence of trypanosomes or more than 100
WBC in CSF [15] could not be confirmed. However, the ES in
Tanzania seemed more severe. Despite same standards of patient
care and management the case fatality rate of ES was higher in
Tanzania. Further investigations are needed to explain these
differences. An immunological background of ES was suspected
for long and recent investigations indicating that a small number
of alleles of the human leukocyte antigen (HLA) were associated
with a significantly increased risk for ES have corroborated this
hypothesis [29]. During the proof-of-concept trial, patients from
Uganda developed more ES than patients in Tanzania
(p = 0.0444). However, the incidence of ES equilibrated between
the centers in the utilization study (p = 0.5176) when steroids were
administered in both centers according the same guidelines. The
evidence for the prevention of ES with steroids in the literature is
conflicting [16,27], however, our data suggest a correlation
between the frequency of ES and the use of prednisolone.
However, the IMPAMEL III program used a low dose of
prednisolone (10 mg). In order to optimize its benefit in the
prevention of ES the use or evaluation of a higher dose is
recommended.
Causes of death are difficult to establish under field conditions.
To avoid bias we used a composite safety endpoint of all-cause
mortality, which is also better suited for comparison of mortality
rates from literature and the historic data. We considered the
historic data from a maximum time period of two years prior to
the trial conduct as the most adequate source for controls, even
though the quality and reporting standards were poorer than the
comprehensive trial documentation.
Efficacy
The historic data did not allow any elucidation of the efficacy of
the standard treatment regimens at end of treatment and/or
during follow up. Blood and CSF examinations at discharge and a
systematic follow-up of patients are not routinely done. Due to the
need for repeated LPs and the long distances to the health centers
the follow-up attendance is generally very low. In T.b. gambiense
endemic regions, patient follow-up is successfully supported by
mobile teams that routinely do large-scale population screenings.
Such teams are inexistent in T.b. rhodesiense areas and other
approaches are needed to support patient follow-up. We engaged
local leaders, community health workers and priests to collect
information on the well-being of patients that did not present for
follow-up examinations. However, to anticipate missing data, the
primary efficacy endpoint was parasitological cure at end of
treatment and the secondary efficacy endpoint was parasitological
cure at follow-up examinations. Given the acuteness of this
disease, relapses are certainly noted by the patients and
communities but not necessarily reported. Therefore, oral
information on the well being of the patients was very valuable
and a satisfactory tool to determine treatment efficacy in the
absence of blood and CSF examinations.
All patients discharge alive (121/137) were free of parasites in
blood and CSF 24 hours after treatment. 12 months after
discharge, the clinical cure rate was 94% in patients enrolled into
the proof-of-concept trial and 96% in all patients directly treated
with melarsoprol. 3 patients died during follow-up (2 in Tanzania,
one in Uganda). 2 deaths were not related to HAT and one had an
unknown cause of death. Overall, 2 relapses were reported, one in
a patient treated with suramin and melarsorpol and one in a
patient directly treated with melarsorpol. In one case a re-infection
was most probable and in the other case, melarsorpol treatment
had to be interrupted for 8 days, before the remaining 4 doses
were administered. Further investigations are needed to identify
the duration of treatment interruption which will require re-
treatment with a full course. Overall, we report a relapse rate of
0.9% (1/107) in patients directly treated with melarsoprol. The
relapse rate for the 10-day melarsoprol schedule in T.b. gambiense
HAT was reported at 7.1% in a controlled clinical trial [23].
The IMPAMEL III program was the first clinical trial program in
T.b rhodesiense HAT conducted in compliance with international
standards (ICH-GCP) and was of high priority by the WHO and
the affected countries. The conduct of the trials strengthened local
capacities, especially for diagnosis, patient management and
reporting. The main bottleneck of clinical research in T.b.
rhodesiense HAT is the overall limited number of patients. A sample
size of minimum 400 patients (200 per arm) would have been
required for the conduct of the IMPAMEL III program in the design
of a randomized control trial. But in two active foci, a total of
138 second stage patients were identified during two years of
active and passive case detection, actively engaging with commu-
nities, district officials for vector control and disease surveillance.
Poor accessibility of affected populations to health care facilities,
the lack of health staff detecting HAT and low sensitivity of the
diagnostic tools hamper case detection. Many patients die
undetected, it is estimated that for each reported death, 12 go
undetected [6].
Today, the biggest need for HAT affected populations is a new
and safe treatment alternative. This will sadly not be the case in
the near future and melarsoprol will continue to play the central
role for the treatment of T.b. rhodesiense HAT. Given the increasing
rates of melarsoprol treatment failures reported in T.b. gambiense
patients [30–33], it can not be excluded that melarsoprol will also
loose some of its efficacy against T.b.rhodesiense. Melarsoprol
treatment failures have been reported in T.b. rhodesiense patients
[34–37] as well as a reduced melarsoprol susceptibility of T.b.
rhodesiense isolates from Tanzania, indicating that drug resistance
may be emerging [38]. Besides the development of novel
compounds, potential combination treatments for second stage
T.b. rhodesiense HAT should be a high priority on the research
agenda.
The results from the IMPAMEL III program show that T.b.
rhodesiense patients treated with the 10-day melarsoprol schedule
were not subject to a higher incidence of serious adverse events (ES
or death) than the historic controls treated with the national
regimens (see Figure 3). In terms of efficacy, we have no evidence
against the use of the 10-day melarsoprol schedule for the
treatment of second stage T.b. rhodesiense HAT. The final data set
used as historic controls was of very good quality. The only
limitation was that the historic controls might have included more
severely sick patients as the patient files did not in detail state if the
patient was unconscious or moribund. The hospitalization time
was reduced from an average of 29 days to 13 days (p,0.0001)
and, together with the fixed dosing of 2.2 mg/kg/day, improves
adherence to treatment from the patient and the provider side;
fewer patients abandon treatment due to the financial burden of a
one month hospital stay and at provider level, significantly less
dosing mistakes are made compared to the varying dosing schemes
of the national regimens. Our data further support the omission of
the suramin-pre-treatment and a standardized use of steroids.
The 10-day schedule offers substantial advantages to the
patients and the health care provider, is a basis for potential
combination treatments and allows harmonizing the highly
heterogeneous treatment protocols currently in use. However, as
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in T.b. gambiense HAT, ES still occur and continue to pose a major
threat to the patients treated. Based on the IMPAMEL III results the
10-day schedule was officially recommended for use in all T.b.
rhodesiense endemic areas at the 30th ISCTRC meeting in Kampala
[39] and respective policy changes are currently ongoing in
Tanzania and Uganda.
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